Leelyn Smith LLC Boosts Stock Position in Veeva Systems Inc. (NYSE:VEEV)

Leelyn Smith LLC grew its holdings in shares of Veeva Systems Inc. (NYSE:VEEV) by 9.9% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 8,253 shares of the technology company’s stock after acquiring an additional 741 shares during the period. Leelyn Smith LLC’s holdings in Veeva Systems were worth $1,735,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in VEEV. Cardinal Capital Management raised its stake in Veeva Systems by 0.3% during the fourth quarter. Cardinal Capital Management now owns 15,727 shares of the technology company’s stock valued at $3,307,000 after buying an additional 44 shares in the last quarter. MassMutual Private Wealth & Trust FSB raised its position in shares of Veeva Systems by 72.5% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 119 shares of the technology company’s stock valued at $25,000 after acquiring an additional 50 shares in the last quarter. Patriot Financial Group Insurance Agency LLC lifted its stake in Veeva Systems by 0.7% during the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 6,975 shares of the technology company’s stock worth $1,467,000 after purchasing an additional 51 shares during the last quarter. CHICAGO TRUST Co NA boosted its holdings in Veeva Systems by 2.9% in the fourth quarter. CHICAGO TRUST Co NA now owns 1,880 shares of the technology company’s stock worth $395,000 after purchasing an additional 53 shares during the period. Finally, Old North State Wealth Management LLC increased its stake in Veeva Systems by 0.4% during the fourth quarter. Old North State Wealth Management LLC now owns 15,351 shares of the technology company’s stock valued at $3,228,000 after purchasing an additional 55 shares during the last quarter. Institutional investors own 88.20% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. Robert W. Baird lifted their price target on shares of Veeva Systems from $283.00 to $285.00 and gave the company an “outperform” rating in a report on Thursday, March 6th. Bank of America lifted their target price on Veeva Systems from $280.00 to $290.00 and gave the company a “neutral” rating in a research note on Friday, December 6th. KeyCorp dropped their price target on Veeva Systems from $285.00 to $255.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 8th. Citigroup upped their price objective on Veeva Systems from $281.00 to $307.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. Finally, JPMorgan Chase & Co. raised their target price on Veeva Systems from $208.00 to $218.00 and gave the company a “neutral” rating in a research note on Monday, December 16th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $255.28.

Veeva Systems Stock Up 1.2 %

NYSE:VEEV opened at $236.93 on Tuesday. The business’s 50-day moving average price is $227.61 and its 200 day moving average price is $221.69. Veeva Systems Inc. has a 52-week low of $170.25 and a 52-week high of $258.93. The firm has a market cap of $38.47 billion, a P/E ratio of 58.50, a PEG ratio of 1.89 and a beta of 0.88.

Veeva Systems Company Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.